Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADEPT-4 phase 3 trial of KarXT for Alzheimer-related psychosis
MOH_2024-11-26_013761Phase 3Recruiting
- Sponsor
- Karuna Therapeutics
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease psychosis (ADP) and Alzheimer's disease (AD) comparing KarXT with Matching placebo (2 arms). Started Nov 2024; status: recruiting.
02
Drugs
xanomeline
03
Conditions
Alzheimer's disease psychosis (ADP)Alzheimer's disease (AD)
Beyond the preview
Go deeper on MOH_2024-11-26_013761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-11-26_013761.